{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:09:39Z","timestamp":1777421379734,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To describe the pharmacology, clinical and safety evidence, and relevance to clinical practice of finerenone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search was conducted utilizing PubMed, MEDLINE, and clinicaltrials.gov with search terms of \u201cfinerenone\u201d and \u201cBAY94-8862.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>All available studies with human participants in English were considered. Studies were included if they investigated drug pharmacology, efficacy, and safety information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis<\/jats:title>\n                    <jats:p>In addition to standard of care with a renin-angiotensin system inhibitor (RASi), finerenone lowered the risk of kidney disease progression (17.8% vs 21.1%) in patients with type 2 diabetes mellitus and chronic kidney disease compared to placebo. Similarly, finerenone reduced cardiovascular risk in patients with type 2 diabetes mellitus and chronic kidney disease compared to placebo (12.4% vs 14.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice<\/jats:title>\n                    <jats:p>It is anticipated that finerenone will be added to therapy after a RASi and a sodium-glucose cotransporter-2 inhibitor, as tolerated, based on adverse events and potassium levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Finerenone offers a unique approach to further delay the progression of chronic kidney disease in patients with type 2 diabetes mellitus. It also provides another option for patients who cannot tolerate RASi or sodium-glucose cotransporter-2 inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280211059577","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T23:10:19Z","timestamp":1642029019000},"page":"1041-1048","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Finerenone: A Novel Mineralocorticoid Receptor Antagonist for Cardiorenal Protection in CKD and T2DM"],"prefix":"10.1177","volume":"56","author":[{"given":"Allissa","family":"Long","sequence":"first","affiliation":[{"name":"Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0273-6148","authenticated-orcid":false,"given":"Marissa","family":"Salvo","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, Storrs, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"bibr1-10600280211059577","unstructured":"Centers for Disease Control and Prevention. Chronic kidney disease surveillance system. Accessed August 16, 2021. https:\/\/nccd.cdc.gov\/CKD."},{"key":"bibr2-10600280211059577","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.74"},{"key":"bibr3-10600280211059577","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"bibr4-10600280211059577","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.06.019"},{"key":"bibr5-10600280211059577","doi-asserted-by":"publisher","DOI":"10.1007\/164_2016_76"},{"key":"bibr6-10600280211059577","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736"},{"key":"bibr7-10600280211059577","unstructured":"Pfizer. Aldactone (spironolactone). New York, NY; 2021. Accessed December 13, 2021. https:\/\/www.pfizer.com\/products\/product-detail\/aldactone."},{"key":"bibr8-10600280211059577","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"bibr9-10600280211059577","unstructured":"Bayer HealthCare Pharmaceuticals, Inc. Kerendia (finerenone). Whippany, NJ; 2021. Accessed December 13, 2021. https:\/\/www.kerendiahcp.com\/."},{"key":"bibr10-10600280211059577","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000091"},{"key":"bibr11-10600280211059577","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.12.016"},{"key":"bibr12-10600280211059577","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht187"},{"key":"bibr13-10600280211059577","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw132"},{"key":"bibr14-10600280211059577","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10081"},{"key":"bibr15-10600280211059577","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"bibr16-10600280211059577","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956"},{"key":"bibr17-10600280211059577","doi-asserted-by":"publisher","DOI":"10.1159\/000503713"},{"key":"bibr18-10600280211059577","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051898"},{"key":"bibr19-10600280211059577","doi-asserted-by":"publisher","DOI":"10.1159\/000503712"},{"key":"bibr20-10600280211059577","unstructured":"Antipolis S. Finerenone benefits patients with diabetes across spectrum of kidney disease. European Society of Cardiology; 2021. Accessed September 27, 2021. https:\/\/www.escardio.org\/The-ESC\/Press-Office\/Press-releases\/Finerenone-benefits-patients-with-diabetes-across-spectrum-of-kidney-disease."},{"key":"bibr21-10600280211059577","unstructured":"ClinicalTrials.gov. Study to evaluate the efficacy (effect on disease) and safety of finerenone on morbidity (events indicating disease worsening) & mortality (death rate) in participants with heart failure and left ventricular ejection fraction (proportion of blood expelled per heart stroke) greater or equal to 40% (FINEARTS-HF). Accessed August 31, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04435626."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280211059577","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280211059577","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280211059577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:36Z","timestamp":1777374996000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280211059577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1177\/10600280211059577"],"URL":"https:\/\/doi.org\/10.1177\/10600280211059577","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,12]]}}}